Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. | Serina Therapeutics is shedding a ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...